The "Small Molecule Drug Discovery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic Area; Process/Phase; and Geography" report has been added to ResearchAndMarkets.com's offering.
The small molecule drug discovery market was valued at US$ 24,976.14 million in 2019 and is projected to reach US$ 50,823.06 million by 2027; it is expected to grow at a CAGR of 9.5% from 2020 to 2027.
There is increase in demand for small molecules in treatment of various chronic as well as rare diseases for which not much treatment options are available. Moreover, the increasing investments and R&D expenditures by the pharmaceutical players towards development of new targets and lead candidates for small molecules are also expected to foster the market growth. However, high cost involved in the drug discovery process expected to restrain the growth of the market during the forecast period.
Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their small size, easy convertibility to oral form, and cost-effectiveness.
The global small molecule drug discovery market is segmented into therapeutic area and process/phase. Based on therapeutic area, the small molecule drug discovery market is further segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas.
The oncology segment held a largest share of the market in 2019; however, the rare diseases segment is anticipated to register a higher CAGR in the market during the forecast period. Based on process/phase, the market is subsegmented into target discovery, target validation, lead generation and refinement, and preclinical development. The lead generation and refinement segment held the largest share of the market in 2019; whereas, target discovery is estimated to register the highest CAGR during the forecast period.
Reasons to Buy:
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the small molecule drug discovery market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global small molecule drug discovery market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Increasing Approval of Small Molecule Drugs
Growing Demand for R&D from Contract Organizations
Rising Adoption of Small Molecules in Chronic Disease Treatments
High Drug Development Cost
Increasing Small Molecule-Based Pipeline
Growing Adoption of Artificial Intelligence in Drug Discovery
Johnson and Johnson Services, Inc.
Teva Pharmaceutical Industries Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ny5r9c
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005679/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900